Application of Renyi entropy for ultrasonic molecular imaging

Department of Medicine, Cardiovascular Division, Washington University School of Medicine, Campus Box 8086, 660 South Euclide Avenue, St. Louis, Missouri 63110-1093, USA.
The Journal of the Acoustical Society of America (Impact Factor: 1.5). 06/2009; 125(5):3141-5. DOI: 10.1121/1.3097489
Source: PubMed


Previous work has demonstrated that a signal receiver based on a limiting form of the Shannon entropy is, in certain settings, more sensitive to subtle changes in scattering architecture than conventional energy-based signal receivers [M. S. Hughes et al., J. Acoust. Soc. Am. 121, 3542-3557 (2007)]. In this paper new results are presented demonstrating further improvements in sensitivity using a signal receiver based on the Renyi entropy. (C) 2009 Acoustical Society of America. [DOI: 10.1121/1.3097489]

Download full-text


Available from: Jeffrey M Arbeit, Apr 08, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previously a new method for ultrasound signal characterization using entropy H(f) was reported, and it was demonstrated that in certain settings, further improvements in signal characterization could be obtained by generalizing to Renyi entropy-based signal characterization I(f)(r) with values of r near 2 (specifically r=1.99) [M. S. Hughes et al., J. Acoust. Soc. Am. 125, 3141-3145 (2009)]. It was speculated that further improvements in sensitivity might be realized at the limit r-->2. At that time, such investigation was not feasible due to excessive computational time required to calculate I(f)(r) near this limit. In this paper, an asymptotic expression for the limiting behavior of I(f)(r) as r-->2 is derived and used to present results analogous to those obtained with I(f)(1.99). Moreover, the limiting form I(f,infinity) is computable directly from the experimentally measured waveform f(t) by an algorithm that is suitable for real-time calculation and implementation.
    The Journal of the Acoustical Society of America 11/2009; 126(5):2350-8. DOI:10.1121/1.3224714 · 1.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Perfluorocarbons (PFCs) are fluorinated compounds that have been used for many years in clinics mainly as gas/oxygen carriers and for liquid ventilation. Besides this main application, PFCs have also been tested as contrast agents for ultrasonography and magnetic resonance imaging since the end of the 1970s. However, most of the PFCs applied as contrast agents for imaging were gaseous. This class of PFCs has been recently substituted by liquid PFCs as ultrasound contrast agents. Additionally, liquid PFCs are being tested as contrast agents for (19)F magnetic resonance imaging (MRI), to yield dual contrast agents for both ultrasonography and (19)F MRI. This review focuses on the development and applications of the different contrast agents containing liquid perfluorocarbons for ultrasonography and/or MRI: large and small size emulsions (i.e. nanoemulsions) and nanocapsules.
    Pharmaceutical Research 11/2009; 27(1):1-16. DOI:10.1007/s11095-009-0001-5 · 3.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We demonstrate a novel approach to ultrasonic detection of molecularly targeted nanoparticle contrast agent accumulation in a xenographic mouse tumor model in vivo. This is accomplished by imaging the entire mouse tumor volume at 15- minute intervals following injection of αvβ3-targeted perfluoro- carbon core nanoparticles. Radiofrequency (RF) data were stored for off-line analysis using signal energy and a limiting form of the R´ enyi entropy suitable for real-time calculation, If,∞. The results indicate that If,∞ may be used to reliably detect accumulation of targeted nanoparticles within 15 minutes of injection without the need for image subtraction, whereas signal energy images showed less sensitivity to nanoparticle accumulation. The ability to detect nanoparticle accumulation without requiring image subtraction or fixing the transducer in place are necessary prerequisites for translation of this technology to the clinic.
    01/2010; DOI:10.1109/ULTSYM.2010.5935829
Show more